Kathryn M Edwards

Prof. Kathryn M Edwards


Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 January 2022 in Annals of Internal Medicine
Verified
Journal Article
Closed access
ISIsaac See
Isaac See
ALAllison Lale
Allison Lale
PMPaige Marquez
Paige Marquez
MSMichael B. Streiff
Michael B. Streiff
AWAllison P. Wheeler
Allison P. Wheeler
DSDavid K. Shay
David K. Shay
Using the Vaccine Adverse Event Reporting System, the number and demographic characteristics of cases of thrombosis with thrombocytopenia syndrome occurring after receipt of COVID-19 vaccines in th... Visual Thrombosis With Thrombocytopenia Syndrome After COVID-19 Vaccination. Using the Vaccine Adverse Event Reporting System, the number and demographic characteristics of cases of thromb... Background: Thrombosis with thrombocytopenia syndrome (TTS) is a potentially life-threatening condition associated with adenoviral-vectored COVID-19 vaccination. It presents similarly to spontaneou...

9 June 2020 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
KMKalpana Manthiram
Kalpana Manthiram
SPSilvia Preite
Silvia Preite
FDFatma Dedeoglu
Fatma Dedeoglu
SDSelcan Demir
Selcan Demir
SOSeza Ozen
Seza Ozen
SZSuiyuan Zhang
Suiyuan Zhang
Significance: In this report we identify genetic susceptibility variants for periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) syndrome, the most common periodic fever syndrome in children. PFAPA shares risk loci atIL12A,STAT4, IL10, andCCR1-CCR3with Behçet’s disease and recurrent aphthous stomatitis, defining a family of Behçet’s spectrum disorders. DifferentialHLAassociations along this spectrum may determine where individual phenotypes fall among the Behçet’s spectrum disorders.

1 July 1993 in The Journal of Infectious Diseases
Verified
Journal Article
Closed access
PDF file
KEKathryn M Edwards
Kathryn M Edwards
The expanded knowledge of the components of Bordetella pertussis has led to the production of new vaccines consisting of one or more components of the organism. The vaccines have been found to be safe and immunogenic in infants and children. Early efficacy studies failed to determine what component of the vaccine and what level of antibody were needed for protection; additional studies with many more vaccines are currently in progress. The role of adults as reservoirs of B. pertussis infections and as victims of symptomatic disease has also been appreciated. Component vaccines have been found to be safe and immunogenic in adults. There is reason to hope that within the next several years the information derived from ongoing and planned studies will support the general use of component acellular pertussis vaccines for the routine immunization of adults and children alike.

1 October 2020 in Vaccine
Verified
Journal Article
Open access
GSGeeta K. Swamy
Geeta K. Swamy
TMTorri D. Metz
Torri D. Metz
KEKathryn M Edwards
Kathryn M Edwards
DSDavid E. Soper
David E. Soper
RBRichard H. Beigi
Richard H. Beigi
ZBZourab Bebia
Zourab Bebia
This study evaluated the safety and immunogenicity of an investigational trivalent group B streptococcus (GBS) vaccine in US pregnant women, transplacental serotype-specific antibody transfer and persistence in infants, and serotype-specific antibodies in breast milk. This randomized, observer-blind, placebo-controlled trial administered one dose of trivalent GBS vaccine (n = 49) or placebo (n = 26) to healthy pregnant 18-40-year-old women at 240/7-346/7 weeks' gestation. Women were enrolled from March 2014 to August 2015. Safety follow-up continued through postpartum day 180. Primary immunogenicity objectives were to evaluate serotype Ia/Ib/III-specific immunoglobulin G (IgG) levels in sera from women on day 1 (pre-vaccination), day 31, delivery and postpartum days 42 and 90, and from infants at birth (cord blood), days 42 and 90. Antibody transfer ratios (cord blood/maternal sera at delivery) and serotype-specific secretory immunoglobulin A (sIgA) and IgG in breast milk after delivery and on postpartum days 42 and 90 were evaluated. The planned sample size was not based on statistical assumptions for this descriptive study. Baseline characteristics were similar between groups. Serious adverse events were reported for 16% of GBS-vaccinated women and 15% of their infants, and 15% of placebo recipients and 12% of their infants; none were fatal or deemed vaccine-related. Serotype-specific IgG geometric mean concentrations (GMCs) were 13-23-fold higher in vaccine vs placebo recipients on day 31 and persisted until postpartum day 90. Median antibody concentrations were substantially higher in women with detectable pre-vaccination antibody concentrations. Antibody transfer ratios in the vaccine group were 0.62-0.82. Infant IgG GMCs and breast milk sIgA GMCs were higher in the vaccine vs the placebo group at all timepoints. Maternal immunization with the trivalent GBS vaccine in US women had a favorable safety profile, elicited antibodies that were transplacentally transferred and persisted in infants for a minimum of 3 months. Clinicaltrials.gov, NCT02046148.

1 April 2014 in Pediatrics
Verified
Journal Article
Closed access
PDF file
AHAnnika M. Hofstetter
Annika M. Hofstetter
KJKathleen Jakob
Kathleen Jakob
NKNicola P. Klein
Nicola P. Klein
CDCornelia L. Dekker
Cornelia L. Dekker
KEKathryn M Edwards
Kathryn M Edwards
PLPhilip LaRussa
Philip LaRussa
OBJECTIVE: Live vaccines are generally contraindicated in patients with DiGeorge syndrome (DGS), a congenital disorder characterized by cellular immune deficiency. Vaccine utilization and safety in this population are not well described. This study examined vaccination patterns and adverse events following live immunization (AEFLI) in these individuals. METHODS: A multicenter retrospective cohort study was conducted in subjects with DGS confirmed by fluorescence in situ hybridization assay (chromosome 22q11.2 microdeletion). Live vaccine-preventable illnesses, vaccination coverage and timeliness, and AEFLIs in the 56-day window after live vaccination were examined. Bivariate and multivariable analyses assessed the impact of demographics medical history, timing of diagnostic confirmation, and preceding immune function on vaccination patterns and AEFLIs. RESULTS: Of 194 subjects, 77% and 75% received measles-mumps-rubella (MMR) and varicella vaccines, respectively; 58% completed recommended vaccinations by age 19 to 35 months. Adverse events occurred after 14% and 20% of MMR and varicella vaccine doses, respectively. Most events were minor, few were serious, and no deaths were reported in post–live vaccination windows. Although early diagnostic confirmation negatively affected live vaccination coverage and timeliness (P < .001), baseline CD4% did not differ between subjects who did or did not receive live vaccines by 12 to 18 months. Among varicella vaccine recipients, those with a subsequent adverse event had a lower preceding CD4% (24.8% ± 7.3%) than those without (35.5% ± 11.7%) (P < .05); no CD4% differences were observed with MMR vaccination. Fourteen unvaccinated subjects experienced live vaccine–preventable illnesses. CONCLUSIONS: Live vaccines were frequently given and generally well-tolerated among patients with DGS with mild-to-moderate immunosuppression.